| Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 77.29 mm | 77.29 mm | 77.29 mm | 77.29 mm | 77.29 mm | 77.29 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 17.67 mm | 15.93 mm | 14.92 mm | 14.17 mm |
| Cash used (since last report) | n/a | n/a | 548.07 mm | 494.12 mm | 462.92 mm | 439.69 mm |
| Cash remaining | n/a | n/a | -470.78 mm | -416.83 mm | -385.63 mm | -362.40 mm |
| Runway (months of cash) | n/a | n/a | -26.6 | -26.2 | -25.8 | -25.6 |
| 13F holders | Current |
|---|---|
| Total holders | 3 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 113.71 mm |
| Total shares | 4.50 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Lilly Ventures Fund I | 2.40 mm | $83.90 mm |
| Novartis Bioventures | 1.76 mm | $24.99 mm |
| LLY Eli Lilly and | 339.19 k | $4.82 mm |
